GPB Passport icon GPB Passport icon Passport
GPB donate icon GPB donate icon Donate
Sign Up For Our Newsletter

News Articles: Amylyx

In college, Amylyx cofounders Josh Cohen and Justin Klee dreamed of finding a treatment for diseases like ALS. When their drug's promise did not pan out, they pulled it voluntarily from the market.

Lots of drug companies talk about putting patients first — but this one actually did

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.

|
By:
  • Jon Hamilton
The drugmaker Amylyx is asking the FDA to approve a new medication for ALS, a fatal neurodegenerative disease. It's possible the agency could greenlight the drug by the end of the month.

FDA seems poised to approve a new drug for ALS, but does it work?

In March, experts who advise the FDA questioned the efficacy of an experimental new drug for ALS. In September, they voted to approve it anyway.

|
By:
  • Jon Hamilton